Hypoxia-activated prodrug and chemotherapy disrupt resistance-associated metabolism in osteosarcoma
Sophie M. Pearce, Neil Alan Cross, Lucy Flint, Malcolm Ronald Clench, David P. Smith, Daniel M. Allwood, Bradley J Wallace, Joseph D. Ready, Gregory R. Hamm, Richard J. A. Goodwin, Laura M. Cole
This study shows that combining hypoxia-activated prodrugs with chemotherapy disrupts metabolic resistance mechanisms in osteosarcoma by targeting ferroptosis, glycolysis, and survival pathways.
bioRxiv · Jun 18, 2026 · PreprintCancer Biology